Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.

Author(s): Lipkin S,  Lee J,  Imagawa D,  Hewitt SM,  Tucker C,  Zell JA,  Wong V,  Garcia A,  Gonzalez R,  Della Zanna G,  Richmond E,  Rodriguez LM,  Bigg M,  Schnoll-Sussmans F,  Meyskens F

Journal: Cancer Prev Res (Phila)

Date: 2011 Apr

Major Program(s) or Research Group(s): GOCRG, CONSORTIA

PubMed ID: 21464031

PMC ID: PMC4492452

Abstract: Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8).